Notably, in HER2-positive breast cancer, BM rates did not significantly differ between the pCR and non-pCR groups, consistent with data from the Memorial Sloan Kettering Cancer Center involving patients treated with trastuzumab- and pertuzumab-based neoadjuvant systemic therapy [17]. The gene discussed is ERBB2; the disease is breast carcinoma.